Switch theme
Sign up to access all valuation multiples
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
2016
5.8K+
LTM Revenue $2.9B
LTM EBITDA -$3.8B
$4.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Moderna has a last 12-month revenue of $2.9B and a last 12-month EBITDA of -$3.8B.
In the most recent fiscal year, Moderna achieved revenue of $3.2B and an EBITDA of -$3.4B.
Moderna expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Moderna valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.8B | $3.2B | XXX | XXX | XXX |
| Gross Profit | $13.5B | $2.1B | XXX | XXX | XXX |
| Gross Margin | 199% | 64% | XXX | XXX | XXX |
| EBITDA | -$3.3B | -$3.4B | XXX | XXX | XXX |
| EBITDA Margin | -49% | -106% | XXX | XXX | XXX |
| Net Profit | $8.4B | -$4.7B | XXX | XXX | XXX |
| Net Margin | 124% | -147% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Moderna's stock price is $27.
Moderna has current market cap of $10.4B, and EV of $4.1B.
See Moderna trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.1B | $10.4B | XXX | XXX | XXX | XXX | $-9.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Moderna has market cap of $10.4B and EV of $4.1B.
Moderna's trades at 1.4x LTM EV/Revenue multiple, and -1.1x LTM EBITDA.
Analysts estimate Moderna's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Moderna and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.1B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | XXX | XXX |
| P/E | -2.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpModerna's NTM/LTM revenue growth is -23%
Moderna's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Moderna's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Moderna's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Moderna and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -53% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -106% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -129% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 142% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 178% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Moderna acquired XXX companies to date.
Last acquisition by Moderna was XXXXXXXX, XXXXX XXXXX XXXXXX . Moderna acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Moderna founded? | Moderna was founded in 2016. |
| Where is Moderna headquartered? | Moderna is headquartered in United States of America. |
| How many employees does Moderna have? | As of today, Moderna has 5.8K+ employees. |
| Who is the CEO of Moderna? | Moderna's CEO is Mr. Stephane Bancel. |
| Is Moderna publicy listed? | Yes, Moderna is a public company listed on NAS. |
| What is the stock symbol of Moderna? | Moderna trades under MRNA ticker. |
| When did Moderna go public? | Moderna went public in 2018. |
| Who are competitors of Moderna? | Similar companies to Moderna include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Moderna? | Moderna's current market cap is $10.4B |
| What is the current revenue of Moderna? | Moderna's last 12-month revenue is $2.9B. |
| What is the current EBITDA of Moderna? | Moderna's last 12-month EBITDA is -$3.8B. |
| What is the current EV/Revenue multiple of Moderna? | Current revenue multiple of Moderna is 1.4x. |
| What is the current EV/EBITDA multiple of Moderna? | Current EBITDA multiple of Moderna is -1.1x. |
| What is the current revenue growth of Moderna? | Moderna revenue growth between 2023 and 2024 was -53%. |
| Is Moderna profitable? | Yes, Moderna is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
